Maryland is open for business and here’s another way our state supports companies seeking capital. Maryland Commerce has launched a new, searchable site that lets you search and find just the right program to fund your business. With the ability to filter by type of program, category or keyword, the Financial Incentives database is a great place to find grants, tax credits, loans and training. Give it a try!
The pharmaceutical industry as a whole is set to benefit from the tax reform vote to take place this week. The general reduction in corporate taxes and a special tax deduction for cash repatriated from overseas should see companies post improved returns to shareholders and a whole lot of cash freed up right away.
Are you worried about protecting your Intellectual Property? What about trademarks? How do you negotiate licenses? Have you thought through your patent strategy? How do you manage patents globally?
Learn about these issues and more from experts at Wilson Sonsini Goodrich & Rosati who will provide advice through 1:1 sessions at the Montgomery County Innovation Center in Rockville this Thursday, January 18th.
Preregistration by noon tomorrow, 1/17, REQUIRED. (Sessions filled on a first come-first served basis.)
The Food and Drug Administration has approved Mumbai-based Lupin’s Tydemy. The product is a generic version of Bayer’s Safyral (drospirenone, ethinyl estradiol, and levomefolate calcium tablets, 3 mg/0.03 mg/0.451 mg and levomefolate calcium tablets, 0.451 mg).
A new research initiative by the University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) and the University of Pittsburgh could finally uncover how T-cells—the “killer cells” that defend the body from microbes—are alerted to hazardous invaders in the body. Funded by a $3.7 million grant from the National Institutes of Health (NIH), the research will be the first to combine X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy for a unique view of the cell’s alert system, which could lead to innovative therapeutics to fight viruses and tumors.
gel-e Inc., a privately held, clinical-stage medical device company, announces the 510(k) clearance of its adhesive bandage by the U.S. Food and Drug Administration (FDA) for prescription (Rx) and over-the-counter (OTC) use.
This new bandage clearance expands the Company’s label to include the management of moderately to heavily exuding chronic wounds and acute wounds. Under medical supervision, this new adhesive bandage may be used for the management of pressure sores, diabetic ulcers, leg ulcers, donor sites and graft sites, surgical wounds, skin abrasions and lacerations, 1st and 2nd degree burns and traumatic wounds. No medical supervision is required for usage in the management of minor cuts, minor scalds and 1st degree burns, and minor abrasions and lacerations. This newly cleared bandage complements gel-e’s existing vascular closure device cleared for the “management of bleeding wounds such as vascular access sites and percutaneous catheters or tubes.”
On the evening of Nov. 7, Steffanie Strathdee sent out a cryptic tweet: “#Phage researchers! I am working with a team to get Burkholderia cepacia phages to treat a 25 y old woman with CF whose infection has failed all #antibiotics. We need lytic non-lysogenic phage URGENTLY to find suitable phage matches. Email if you can help!” The message was retweeted nearly 400 times.
Humans and bacteria have been clashing for as long as both have inhabited the Earth, and for decades now, humans have had the upper hand. Starting with penicillin in 1942, antibiotics have brought previously untreatable maladies like tuberculosis under control and made surgery far safer.
MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today the receipt of a Phase I grant from the National Center for Advancing Translations Sciences under auspices of the Small Business Innovation Research (SBIR) program of the National Institutes of Health. The $250,000 grant under the Award Number R43TR002231 is focused on demonstrating the utility of a non-infectious Minute Virus of Mice-Virus Like Particle for predicting viral clearance during biopharmaceutical process development.
Andreessen Horowitz, a Menlo Park, CA-based venture capital firm, has launched its $450m second bio fund.
Bio Fund II will focus on investing in companies at the intersection of biology and engineering.
